Eisenhofer G, Aneman A, Hooper D, Rundqvist B, Friberg P
Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
J Neurochem. 1996 Apr;66(4):1565-73. doi: 10.1046/j.1471-4159.1996.66041565.x.
This study used regional differences in plasma concentrations of norepinephrine and its metabolites to examine how production of the transmitter by sympathetic nerves, in particular, those innervating mesenteric organs, is integrated with metabolism by the liver and elimination by the kidneys. Higher concentrations of norepinephrine, its glycol metabolites 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol and their sulfate conjugates in portal venous than arterial plasma indicate substantial production of norepinephrine by mesenteric organs (15.5 nmol/min). Much lower concentrations of norepinephrine and its glycol metabolites in plasma leaving than entering the liver indicate their efficient hepatic removal (20 nmol/min). Higher concentrations of vanillylmandelic acid in the hepatic outflow than inflow indicate that this metabolic end product is produced largely from the norepinephrine and glycol metabolites removed by the liver. Renal elimination of vanillylmandelic acid (18-20 nmol/min), produced mainly by the liver (17 nmol/min), and of 3-methoxy-4-hydroxyphenylglycol sulfate (7-9 nmol/min), produced largely by mesenteric organs (7 nmol/min), compromised 86-91% of the total renal elimination of norepinephrine metabolites. The results show that mesenteric organs produce about one-half of the norepinephrine formed in the body. The liver removes substantial amounts of circulating norepinephrine and its glycol metabolites and converts these compounds to vanillylmandelic acid, which is then eliminated from the body by the kidneys. The sulfate conjugates are also metabolic end products eliminated by the kidneys. However, these metabolites are produced by extrahepatic tissues, in particular, mesenteric organs, which represent a significant source of sulfate-conjugated norepinephrine and 3,4-dihydroxyphenylglycol, and the main source of sulfate-conjugated 3-methoxy-4-hydroxyphenylglycol.
本研究利用去甲肾上腺素及其代谢产物血浆浓度的区域差异,来研究交感神经,特别是支配肠系膜器官的交感神经所产生的递质,是如何与肝脏的代谢及肾脏的清除过程相互整合的。门静脉血浆中去甲肾上腺素、其二醇代谢产物3,4-二羟基苯乙二醇和3-甲氧基-4-羟基苯乙二醇及其硫酸酯结合物的浓度高于动脉血浆,这表明肠系膜器官能大量产生去甲肾上腺素(15.5纳摩尔/分钟)。离开肝脏的血浆中去甲肾上腺素及其二醇代谢产物的浓度远低于进入肝脏的血浆,这表明肝脏能有效清除这些物质(20纳摩尔/分钟)。肝流出液中香草扁桃酸的浓度高于流入液,这表明这种代谢终产物主要由肝脏清除的去甲肾上腺素和二醇代谢产物产生。肾脏对主要由肝脏产生(17纳摩尔/分钟)的香草扁桃酸(18 - 20纳摩尔/分钟)以及主要由肠系膜器官产生(7纳摩尔/分钟)的3-甲氧基-4-羟基苯乙二醇硫酸酯(7 - 9纳摩尔/分钟)的清除,占去甲肾上腺素代谢产物肾脏总清除量的86 - 91%。结果表明,肠系膜器官产生的去甲肾上腺素约占体内生成总量的一半。肝脏能清除大量循环中的去甲肾上腺素及其二醇代谢产物,并将这些化合物转化为香草扁桃酸,然后由肾脏排出体外。硫酸酯结合物也是由肾脏清除的代谢终产物。然而,这些代谢产物是由肝外组织产生的,特别是肠系膜器官,肠系膜器官是硫酸酯结合的去甲肾上腺素和3,4-二羟基苯乙二醇的重要来源,也是硫酸酯结合的3-甲氧基-4-羟基苯乙二醇的主要来源。